Abstract
Drug use is a risk factor for the chronification of primary headaches and the development of secondary headaches. Forms of persistent post COVID headache have been reported, which may be due in part to the headache attributed to COVID 19 but also to drug use. The aim of the study was to analyze post-COVID drug use in subjects with headaches and to compare with preinfection levels. Material and method: An online survey was done. Questionnaires were completed by subjects who had experienced COVID 19 infection and had a headache. The questionnaire was structured in 72 questions validated and approved by the institutional bioethics committee. Completion time - 20 min. The analysis of drug use was performed and the possible prediction factors were determined by simple multivariate regression. Results: The study included 140 subjects with a mean age of 37.44 ± 10.18 years, 88.6% being women. They reported average drug use for the treatment of pain (days / month) before COVID 19 infection = 4.15 ± 4,041 (days / month) vs. during COVID 19 infection = 9.80 ± 7.742 (days / month) vs post COVID period = 7.7 ± 8.243 (days /month) (½ p <0.000, 1/3 p <0.026). Multivariate regression analysis allowed the prediction of factors that influence drug use. Model 1 - R2 = 0.471, p = 0.031, F = 2.13, df = 15; Predictor 1 = previous drug use before COVID: B = 0.641, β = 0.408, t = 2.85, p = 0.017; Predictor 2 = post COVID headache: B = -2.33, β = -0.293, t = -2.09, p = 0.044; Predictor 3 = post COVID depression: B = - 4.00, β = -0.300, t = -2.09, p = 0.050. Model 3 - R2 = 0.204, p = 0.004, F = 6.26, df = 2, Predictor 1 = drug use before COVID: B = 0.595, β = 0.379, t = 2.9, p = 0.005, Predictor 2 = vertigo post COVID: B = 2.183, β = 0.319, t = 2.462, p = 0.017 Conclusion: Drug use in the post-COVID period is associated with several factors but predictive value showed drug use before infection, the nature of post-COVID headache, depression, and vertigo in the post-COVID period.
Highlights
A fost efectuată analiza de corelație a consumului de medicamente care a determinat că în perioada anterioară infectării cu COVID 19, consumul de medicamente a fost determinat în special de frecvența acceselor de cefalee (r= 0.630, p=0.000)
2. Persistența cefaleei în perioada post COVID poate fi determinată de consumul de medicamente din care motiv este imperativ cuantificarea și monitorizarea acestuia la subiecții cu cefalee primară sau secundară
Summary
Cefaleea persistentă post COVID este o cefalee secundară care poate apărea de novo sau se poate asocia unei cefalei primare preexistente fiind acompaniată de consum crescut de medicamente[5]. Au fost validate 140 chestionare pentru care au fost analizate consumul de medicamente anterior infectării, în timpul suportării infecției și post COVID 19.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Bulletin of the Academy of Sciences of Moldova. Medical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
